Class/mechanism: Photosensitizing agent used in photodynamic therapy (PDT), comprised of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units. Light from photodynamic therapy excites porphyrin and results in the propagation of radical reactions, including the formation of superoxide and hydroxyl radicals. Ischemic necrosis due to vascular occlusion thought to be mediated by thromboxane A2 (TXA2) release and has also been observed.
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
Also known as
- Brand name: Photofrin